Skip to main content
TipRanks
Go Ultimate75% OFF

InDex Pharmaceuticals Holding AB (1NP1) AI Stock Analysis

5 Followers
DE:1NP1

InDex Pharmaceuticals Holding AB

(Frankfurt:1NP1)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Exceptionally low leverageMinimal debt materially reduces interest and refinancing pressure, giving InDex greater financial flexibility than a highly leveraged biotech. This balance-sheet strength can help preserve strategic options and support continued clinical or partnering activity despite current losses.
Negative Factors
Persistent cash burnOngoing negative operating and free cash flow means the business is consuming cash rather than funding itself. If this pattern continues, InDex will need successful partnering, additional financing, or other capital sources to sustain clinical development and operations.

InDex Pharmaceuticals Holding AB (1NP1) vs. iShares MSCI Germany ETF (EWG)

-80%-60%-40%-20%0%20%DE:1NP1-64.40%EWG+7.58%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 106.56M
Dividend Yield
―
Average Volume (3M)
8,403
Price to Earnings (P/E)
-1.1
Beta (1Y)
0.10
Revenue Growth
-180.59%
EPS Growth
-265.58%
Country
Germany
Employees
8
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

InDex Pharmaceuticals Holding AB Business Overview & Revenue Model

Company Description

Flerie AB (publ) functions as a venture capital entity, concentrating its investments on nascent businesses. The firm actively seeks to fund biotechnology and pharmaceutical companies dedicated to advancing drug discovery and development, or producin...

InDex Pharmaceuticals Holding AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:1NP1 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:CANTASE:CANTA83OutperformSEK 386.26M2.0163.09%―――
SE:HNSASE:HNSA60NeutralSEK 5.04B-6.27――68.88%10.63%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:VICOSE:VICO44NeutralSEK 2.99B-5.65-55.97%―-54.97%-1.66%
SE:BINVSE:BINV43NeutralSEK 180.96M-0.37-128.54%―-83.67%-50.29%
SE:SYNACTSE:SYNACT43NeutralSEK 804.98M-7.66-60.58%――14.35%

* Healthcare Sector Average

Performance Comparison

-50%0%50%DE:1NP1SE:HNSASE:BINVSE:SYNACTSE:VICOSE:CANTADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:1NP1 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:1NP1InDex Pharmaceuticals Holding AB1.02-1.86-64.56%
SE:HNSAHansa Biopharma48.1821.0277.39%
SE:BINVBioInvent International AB2.94-28.31-90.59%
SE:SYNACTSynAct Pharma AB13.58-7.27-34.87%
SE:VICOVicore Pharma Holding AB10.320.201.98%
SE:CANTACantargia AB1.31-1.86-58.64%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.